BETA - What is some of the most promising research being done to treat chronic lymphocytic leukemia?

What is some of the most promising research being done to treat chronic lymphocytic leukemia? So treatment of CLL has changed a lot over the last 10 years, and that's all due to the ongoing research that has taken place over the last 10 years. The most promising agents which have already been approved are the BTK inhibitors, or the Bruton styrocyn kinase inhibitors, of which there are two kinds. They're covalent BTK inhibitors and non-covalent BTK inhibitors. The covalents, we have three approved agents. We have Abrutneb, we have A. cal. Abrutneb, and we have Xana Abrutneb. And of the non-covalent, we just last year in December 2023 had Pert Abrutneb approved as the first agent. Then we have the second class of drugs called BCL2 inhibitor, of which we have Monadoclax as the approved FDA agent. But there are currently two in clinical trials that have shown very promising results. We have Laceftoclax and Sondrotoclax. And there are other agents that are in development. Our therapy was recently approved for patients with relapsed CLL. Then we have what are called bispecific monoclonal antibodies, or BITES cells. Those are also in clinical trials. And then we have BTK degraders that are also in clinical trials. So lots of exciting work being done around the therapy for CLL. I'm excited about some of the new combination therapies that we may be able to offer our patients where the treatment is usually combined of pills, oral medications that are easier to take than having to come in for long infusions. And also that are fixed durations, rather than taking an indefinite treatment, taking a period of time where you're taking treatment and then you're off treatment and we observe you afterwards. I think those will provide good efficacy, good response in drug, good response to treatment, but also will improve our patients' quality of lives where they don't have to be in the clinic so much.